Vaxcyte, Inc. (NASDAQ:PCVX) Expands U.S. Manufacturing And Eyes Near-Term Technical Re-Acceleration
Vaxcyte presents a mixed signal set: strengthening commercial-readiness steps offset by short-term bearish technical momentum, while fundamentals show deep R&D investment and a strong cash buffer consistent with a fair-valued biotech development profile.








